{"nctId":"NCT00402831","briefTitle":"ProQuad® Intramuscular vs Subcutaneous","startDateStruct":{"date":"2006-10-06","type":"ACTUAL"},"conditions":["Measles","Mumps","Rubella","Varicella"],"count":405,"armGroups":[{"label":"Intramuscular ProQuad®","type":"EXPERIMENTAL","interventionNames":["Biological: ProQuad®"]},{"label":"Subcutaneous ProQuad®","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: ProQuad®"]}],"interventions":[{"name":"ProQuad®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy participant of either gender,\n* Age 12 to 18 months,\n* Negative clinical history of measles, mumps, rubella, varicella and zoster,\n* Consent form signed by both holders of the parental authority or by the legal representative\n* Holder(s) of the the parental authority / legal representative able to understand the protocol requirements and to fill in the Diary Card.\n\nExclusion Criteria:\n\n* Prior receipt of measles, mumps, rubella and/or varicella vaccine either alone or in any combination,\n* Any recent (≤30 days) exposure to measles, mumps, rubella, varicella and/or zoster\n* Any recent (≤3 days) history of febrile illness\n* Any severe chronic disease,\n* Active untreated tuberculosis,\n* Known personal history of seizure disorder,\n* Any known blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems,\n* Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,\n* Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity including those resulting from corticosteroid \\[any long-term (≥14 days) administration of systemic corticosteroid therapy given daily or on alternate days at high doses (≥2 mg/kg/day prednisone equivalent or ≥20 mg/day if weight more than 10 kg) within the previous 30 days\\] or other immunosuppressive therapy,\n* Any previous (≤ 150 days) receipt of immune globulin or any blood-derived product or scheduled to be administered through Visit 3,\n* Any recent (≤7 days) tuberculin test or scheduled tuberculin test through Visit 3,\n* Any recent (≤30 days) receipt of an inactivated or a live vaccine or scheduled vaccination through Visit 3,","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"18 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Meeting Antibody Response Rate Criteria Six Weeks After Completing ProQuad® Treatment","description":"Antibody response rates were determined 6 weeks after the second dose of IM or SC ProQuad®. Measles, mumps and rubella antibody levels were determined using enzyme-linked immunosorbent assay (ELISA) and varicella antibody levels were determined with glycoprotein-based ELISA (gpELISA). Response rates were determined as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre \\<255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre \\<10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre \\<10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre \\<1.25 gpELISA units/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"99.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Meeting Antibody Response Rate Criteria Four Weeks After the First ProQuad® Dose","description":"Antibody response rates were determined 4 weeks after the first dose of IM or SC ProQuad®. Measles, mumps and rubella antibody levels were determined using ELISA and varicella antibody levels were determined with gpELISA. Response rates were determined as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre \\<255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre \\<10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre \\<10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre \\<1.25 gpELISA units/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"97.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null},{"groupId":"OG001","value":"91.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"98.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Geometric Mean Titres (GMT) to Measles Four Weeks After the First ProQuad® Dose","description":"Antibody titre levels to measles were determined 4 weeks after the first dose of IM or SC ProQuad®. Measles antibody levels were determined using ELISA. Titre levels were determined in participants with baseline measles titre \\<255 mIU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4058.7","spread":null},{"groupId":"OG001","value":"3327.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody GMT to Mumps Four Weeks After the First ProQuad® Dose","description":"Antibody titre levels to mumps were determined 4 weeks after the first dose of IM or SC ProQuad®. Mumps antibody levels were determined using ELISA. Titre levels were determined in participants with baseline mumps titres \\<10 ELISA Ab units mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120.0","spread":null},{"groupId":"OG001","value":"101.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody GMT to Rubella Four Weeks After the First ProQuad® Dose","description":"Antibody titre levels to rubella were determined 4 weeks after the first dose of IM or SC ProQuad®. Rubella antibody levels were determined using ELISA. Titre levels were determined in participants with baseline rubella titre \\<10 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","spread":null},{"groupId":"OG001","value":"50.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody GMT to Varicella Four Weeks After the First ProQuad® Dose","description":"Antibody titre levels to varicella were determined 4 weeks after the first dose of IM or SC ProQuad®. Varicella antibody levels were determined with gpELISA. Titre levels were determined in participants with baseline varicella antibody titre \\<1.25 gpELISA units/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"23.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody GMT to Measles Six Weeks After Completing ProQuad® Treatment","description":"Antibody titre levels to measles were determined 6 weeks after the second dose of IM or SC ProQuad®. Measles antibody levels were determined using ELISA. Titre levels were determined in participants with baseline measles titre \\<255 mIU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3953.7","spread":null},{"groupId":"OG001","value":"3748.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody GMT to Mumps Six Weeks After Completing ProQuad® Treatment","description":"Antibody titre levels to mumps were determined 6 weeks after the second dose of IM or SC ProQuad®. Mumps antibody levels were determined using ELISA. Titre levels were determined in participants with baseline mumps titre \\<10 ELISA Ab units mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157.9","spread":null},{"groupId":"OG001","value":"168.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody GMT to Rubella Six Weeks After Completing ProQuad® Treatment","description":"Antibody titre levels to rubella were determined 6 weeks after the second dose of IM or SC ProQuad®. Rubella antibody levels were determined using ELISA. Titre levels were determined in participants with baseline rubella titre \\<10 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8","spread":null},{"groupId":"OG001","value":"94.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody GMT to Varicella Six Weeks After Completing ProQuad® Treatment","description":"Antibody titre levels to varicella were determined 6 weeks after the second dose of IM or SC ProQuad®. Varicella antibody levels were determined with gpELISA. Titre levels were determined in participants with baseline varicella antibody titre \\<1.25 gpELISA units/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"358.1","spread":null},{"groupId":"OG001","value":"261.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing an Injection-site Adverse Event (AE) or Vaccine-related Systemic AE After the First ProQuad® Dose","description":"An AE is any untoward medical occurrence in a participant administered an investigational medicinal product (IMP) and which does not necessarily have a causal relationship with the IMP. Injection-site AEs (e.g., erythema, swelling, pain) and systemic vaccine-related AEs (e.g., pyrexia) were AEs of interest.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null},{"groupId":"OG001","value":"8.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing an Injection-site AE or Vaccine-related Systemic AE After the Second ProQuad® Dose","description":"An AE is any untoward medical occurrence in a participant administered an IMP and which does not necessarily have a causal relationship with the IMP. Injection-site AEs (e.g., erythema, swelling, pain) and systemic vaccine-related AEs (e.g., pyrexia) were AEs of interest.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":null},{"groupId":"OG001","value":"29.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Discontinuing From Study Therapy Due to an AE After the First ProQuad® Dose","description":"An AE is any untoward medical occurrence in a participant administered an IMP and which does not necessarily have a causal relationship with the IMP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":202},"commonTop":["Pyrexia","Injection site erythema","Ear infection","Injection site pain","Nasopharyngitis"]}}}